KDIGO Consensus Reframes Kidney Function Changes in Heart Failure
This KDIGO Controversies Conference report clarifies how renal pharmacists should interpret creatinine shifts and deploy overlapping cardiorenal therapies in patients with concurrent heart failure and chronic kidney disease.
CKD and HF coexistence demands integrated management strategies.
Chronic kidney disease (CKD) and heart failure (HF) often coexist, increasing patient risks and complicating management. Emerging therapies like sodium-glucose cotransporter-2 inhibitors show promise, but evidence in advanced CKD is limited. Guideline-recommended therapies for HF causing minor kidney function decline should generally not be discontinued. CKD and HF management requires a nuanced, integrated approach.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Lam CSP, Bozkurt B, Cherney DZI, Ezekowitz JA, Jardine MJ, Khan SS, Madero M, Sarnak MJ, Ter Maaten JM, Cheung M, King JM, Grams ME, Jadoul M, Bansal N, Conference Participants
Citation:Lam CSP, Bozkurt B, Cherney DZI, et al. Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney international. 2026;109(6):1095-1113. doi:10.1016/j.kint.2025.10.011
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.